Table 3 Multivariate analysis of factors associated with underutilization of inhaled corticosteroids in TASH chest clinic from 1 May to 31 September 2014 (n = 131)
Variables | Underutilization of ICS | COR (95% CI) | AOR | |
|---|---|---|---|---|
Yes n (%) | No n (%) | |||
Monthly income in ETB (=120)a | ||||
 ≤1200 | 56 (78.3) | 17 (21.7) | 8.10 (2.19–30.00) a | 5.35 (1.10–22.16) |
 1201–2500 | 15 (51.9) | 13 (48.1) | 2.42 (0.59–9.82) | 1.46 (0.29–7.22) |
 >2500 | 10 (30.8) | 9 (69.2) | 1.01 | 1.00 |
Duration of asthma in years | ||||
 ≤21 | 36 (56.9) | 28 (43.1) | 1.00 | 1.00 |
 >21 | 47 (72.1) | 20 (27.9) | 1.96 (0.91–4.21) | 1.49 (0.54–4.15) |
Comorbidity | ||||
 Yes | 54 (71.8) | 23 (28.2) | 2.15 (1.001–4.65) a | 3.10 (1.11–8.69) a |
 No | 29 (54.2) | 25 (45.2) | 1.00 | 1.00 |
Types of ICS products prescribed | ||||
 ICS alone | 68 (73.9) | 26 (26.1) | 4.44 (1.88–10.62) a | 4.39 (1.49–12.92) a |
 ICS with LABA | 15 (38.7) | 21 (61.3) | 1.00 | 1.00 |
Severity of asthma | ||||
 Mild | 28 (61.9) | 18 (38.1) | 1.00 | 1.00 |
 Moderate | 23 (52.5) | 21 (47.5) | 0.68 (0.28–1.64) | 0.545 (0.16–1.87) |
 Severe | 32 (81.1) | 9 (18.9) | 2.63 (0.94–7.40) | 3.17 (0.86–11.75) |